ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.
NCT ID: NCT00291759
Last Updated: 2013-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
3858 participants
INTERVENTIONAL
1996-01-31
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Secondary Adjuvant Long Term Study With Arimidex
NCT00295620
Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients
NCT00309491
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
NCT00295646
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
NCT00287534
Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer
NCT00002529
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tamoxifen
Anastrozole
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 6 lymph nodes examined.
* Good or intermediate tumour differentiation.
* \<6 weeks before start of adjuvant therapy.
* Oestrogen or Progesterone positive
Exclusion Criteria
* Preoperative hormonal/antihormonal/radiation/cytoxic chemo. Second malignant tumour/status post second malignant tumour.
* In-situ/T4 carcinoma.
* Age \>80 years.
* World Health Organisation performance index \>3.
* Serious accompanying diseases
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raimund Jakesz, MD
Role: PRINCIPAL_INVESTIGATOR
Austrian Breast and Colorectal Cancer Study Group
AstraZeneca Austria Medical Director, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Amstetten, , Austria
Research Site
Bad Ischl, , Austria
Research Site
Baden, , Austria
Research Site
Bregenz, , Austria
Research Site
Bruck/Mur, , Austria
Research Site
Dornbirn, , Austria
Research Site
Eisenstadt, , Austria
Research Site
Feldbach, , Austria
Research Site
Feldkirch, , Austria
Research Site
Freistadt, , Austria
Research Site
Fürstenfeld, , Austria
Research Site
Gmünd, , Austria
Research Sites
Graz, , Austria
Research Site
Güssing, , Austria
Research Site
Hainburg an der Donau, , Austria
Research Site
Hartberg, , Austria
Research Site
Hollabrunn, , Austria
Research Site
Horn, , Austria
Research Site
Innsbruck, , Austria
Research Site
Judenburg, , Austria
Research Site
Kirchdorf, , Austria
Research Site
Klagenfurt, , Austria
Research Sites
Klosterneuburg, , Austria
Research Site
Kufstein, , Austria
Research Site
Leoben, , Austria
Research Sites
Linz, , Austria
Research SIte
Melk, , Austria
Research Site
Mistelbach, , Austria
Research Site
Mödling, , Austria
Research Site
Neunkirchen, , Austria
Research Site
Oberpullendorf, , Austria
Research Site
Oberwart, , Austria
Research Site
Ried im Innkreis, , Austria
Research Site
Rohrbach, , Austria
Research Site
Rottenmann, , Austria
Research Site
Saint Poelton, , Austria
Research Site
Saint Veit/Glan, , Austria
Research Site
Salzburg, , Austria
Research Site
Schärding, , Austria
Research Site
Scheibbs, , Austria
Research Site
Schladming, , Austria
Research Site
Schwarzach/Pongau, , Austria
Research Site
Spittal/Drau, , Austria
Research Site
Steyr, , Austria
Research Site
Tulln, , Austria
Research Sites
Vienna, , Austria
Research Site
Villach, , Austria
Research Site
Vöcklabruck, , Austria
Research Site
Waidhofen/Thaya, , Austria
Research Site
Wels, , Austria
Research Site
Wolfsberg, , Austria
Research Site
Zams, , Austria
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S, Schaper C, Fesl C, Gnant M. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol. 2015 Mar 10;33(8):916-22. doi: 10.1200/JCO.2014.55.6894. Epub 2014 Oct 20.
Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen TO; Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014 Feb;25(2):339-45. doi: 10.1093/annonc/mdt494. Epub 2013 Dec 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ABCSG 8
Identifier Type: -
Identifier Source: secondary_id
1033AU/0002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.